Kostas Biliouris

Do you think that your competitor will be able to leverage nucresiran's combo data or it will be specific to nucresiran

Have you seen any seasonality during the fourth quarter, potentially patients who pushed the injection to the next quarter because of the holidays and whether this can be a tailwind to 2026

whether you see the majority of the early AMVUTTRA uptake coming from switch patients or new patients

what are your thoughts around step edits for commercial insured patients who represent about 20%